Down 88%, Could Editas Medicine Be a Good Investment Now?

It's been a few years since the average investor behaved as if no challenge was too tough for America's biopharmaceutical industry. In turn, shares of gene-editing startup Editas Medicine (EDIT -0.98%) have collapsed by about 88% over the past three years despite recent positive news regarding its experimental therapies and intellectual property.Editas is driving its first CRISPR-based therapy toward commercialization. Following approval of a similar treatment from CRISPR Therapeutics and partner Vertex Pha ...